Showing results (31-40 of 43) with videos related to
Sort By:
Pageof 5
Cancer Immunology, Immunotherapy : CII|August 9, 2020
Chemotherapy negatively impacts the tumor immune microenvironment in NSCLC: an analysis of pre- and post-treatment biopsies in the multi-center SAKK19/09 studyM A Amrein, E D Bührer, M L Amrein, et al.Journal of the National Cancer Institute|March 22, 2001
Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic originsO Gautschi, S Tschopp, R A Olie, et al.Schweizerische Medizinische Wochenschrift|June 23, 1998
[Acute myocardial infarct in Switzerland: results from the PIMICS Heart Infarct Register. PIMICS Project (Prospective Ischemia Myocardial Infarction Captopril Survey)]B Naegeli, O Bertel, P Urban, et al.Cancer Letters|April 24, 2007
Origin and prognostic value of circulating KRAS mutations in lung cancer patientsO Gautschi, B Huegli, A Ziegler, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 29, 2000
A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cellsU Zangemeister-Wittke, S H Leech, R A Olie, et al.Lung Cancer (Amsterdam, Netherlands)|June 15, 2014
Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05)M Joerger, F Baty, M Früh, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 10, 2012
Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07D Helbling, G Bodoky, O Gautschi, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 25, 2015
Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohortJ Mazières, F Barlesi, T Filleron, et al.Lung Cancer (Amsterdam, Netherlands)|December 3, 2023
Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort studyA Schuler, J Huser, S Schmid, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 30, 2025
Early and locally advanced non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up†A Zer, M-J Ahn, F Barlesi, et al.Pageof 5